Application of nanotechnology to cancer radiotherapy

被引：113
作者：
Mi Y. [1 ,2 ]
Shao Z. [3 ]
Vang J. [1 ,2 ]
Kaidar-Person O. [1 ,2 ]
Wang A.Z. [1 ,2 ]
机构：
[1] Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, 27599, NC
[2] Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, 27599, NC
[3] Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou
来源：
Cancer Nanotechnology | 2016年 / 7卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Cancer nanotechnology; Combination therapy; Image-guided radiotherapy; Radioisotope; Radiosensitizer; Radiotherapy;
D O I：
10.1186/s12645-016-0024-7
中图分类号：
学科分类号：
摘要：
Radiotherapy has been an integral treatment modality for cancer. The field arose from and progressed through innovations in physics, engineering, and biology. The evolution of radiation oncology will rely on the continued adoption of advances from other fields. A new area of science that possesses the ability to impact radiation oncology is nanomedicine. Materials on the nanoscale provide many unique properties such as enhanced permeability and retention effect and superparamagnetism that are well suited for applications in radiation oncology. In this review, we will provide a comprehensive summary on how nanotechnology can improve cancer radiotherapy in aspects of treatment delivery and monitoring as well as diagnosis. © 2016, The Author(s).
引用
收藏
相关论文
共 86 条
[1]  
Al-Dimassi S., Abou-Antoun T., El-Sibai M., Cancer cell resistance mechanisms: a mini review, Clin Transl Oncol, 16, 6, pp. 511-516, (2014)
[2]  
Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., Van't Veer M.B., Bartelink H., van Leeuwen F.E., Long-term cause-specific mortality of patients treated for Hodgkin’s disease, J Clin Oncol, 21, 18, pp. 3431-3439, (2003)
[3]  
Au K.M., Hyder S.N., Wagner K., Shi C., Kim Y.S., Caster J.M., Wang A.Z., Direct observation of early-stage high-dose radiotherapy-induced vascular injury via basement membrane-targeting nanoparticles, Small, 11, 48, pp. 6404-6410, (2015)
[4]  
Au K.M., Min Y., Tian X., Zhang L., Perello V., Caster J.M., Wang A.Z., Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles, ACS Nano, 9, 9, pp. 8976-8996, (2015)
[5]  
Barcellos-Hoff M.H., Derynck R., Tsang M.L., Weatherbee J.A., Transforming growth factor-beta activation in irradiated murine mammary gland, J Clin Investig, 93, 2, pp. 892-899, (1994)
[6]  
Barcellos-Hoff M.H., Park C., Wright E.G., Radiation and the microenvironment—tumorigenesis and therapy, Nat Rev Cancer, 5, 11, pp. 867-875, (2005)
[7]  
Barenholz Y., Doxil(R)—the first FDA-approved nano-drug: lessons learned, J Control Release, 160, 2, pp. 117-134, (2012)
[8]  
Barker H.E., Paget J.T., Khan A.A., Harrington K.J., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence, Nat Rev Cancer, 15, 7, pp. 409-425, (2015)
[9]  
Baskar R., Lee K.A., Yeo R., Yeoh K.W., Cancer and radiation therapy: current advances and future directions, Int J Med Sci, 9, 3, pp. 193-199, (2012)
[10]  
Bernier J., Hall E.J., Giaccia A., Radiation oncology: a century of achievements, Nat Rev Cancer, 4, 9, pp. 737-747, (2004)
123456789